Moderated by:
Neil Spooner
Director, Spooner Bioanalytical Solutions
Neil is the Founder of Spooner Bioanalytical Solutions, helping companies to integrate biological fluid microsampling, and patient centric sampling and analysis into workflows. He also works with organisations to develop technologies and introduce them to the market. Neil also assists organisations with their understanding of emerging trends in the pharmaceutical industry and bioanalysis. Neil is a Senior Visiting Research Fellow at the University of Hertfordshire, Editor in Chief of the journal, Bioanalysis, Founder of the Patient Centric Sampling Interest Group and Co-Chair of the Reid Bioanalytical Forum. He has published over 70 peer reviewed manuscripts and delivered over 50 podium presentations.
Speakers:
Enaksha Wickremsinhe
Senior Director, Eli Lilly & Company
Enaksha is a Senior Director at Eli Lilly and Company. He has over 20 years of bioanalytical experience in quantitative LC/MS/MS supporting all phases of drug development. His expertise includes microsampling for PK (preclinical and clinical) and patient centric blood sampling for decentralized clinical trials. Enaksha has also served as an ADME project leader for several oncology assets. He is the recipient of several awards from Eli Lilly and Company, including the President’s award, the Global 3Rs award, the Innovator award, and the Pediatric Excellence award. Enaksha received his Ph.D. from the Pennsylvania State University. He is the co-chair of the AAPS Microsampling and Patient Centric Sampling subgroup.
Jeff Silverman
Senior Research Fellow, Edgewise Therapeutics
Dr Jeffrey Silverman is currently Senior Research Fellow at Edgewise Therapeutics. Formerly he was Vice President of Early Development at Jazz Pharmaceuticals. Previously, he held positions at Gilead Sciences, Talon Therapeutics and Sunesis Pharmaceuticals. Dr Silverman also holds an Adjunct Professor faculty position in the Department of Bioengineering and Therapeutic Sciences of the University of California in San Francisco.
Dr Silverman has had a significant role in the preclinical and clinical development of both small and large molecule therapeutics for a number of diseases, in particular in oncology and immunology. He has a passion to understand the PK/PD of novel drug candidates. He has also made significant contributions to the field of drug transporters and their role in pharmacokinetics and pharmacodynamics.
